# Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants

> **NCT06106074** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 71 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Tolebrutinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06106074
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-10
- **Primary completion:** 2022-05-23
- **Final completion:** 2022-05-23
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2023-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06106074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06106074, "Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06106074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*